AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
59 hedge funds and large institutions have $36.2M invested in AVEO Pharmaceuticals, Inc. in 2019 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 21 closing their positions.
53% more call options, than puts
Call options by funds: $3.19M | Put options by funds: $2.09M
13% more capital invested
Capital invested by funds: $31.9M → $36.2M (+$4.27M)
0% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 15
19% less funds holding
Funds holding: 73 → 59 (-14)
62% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$1.47M |
| 2 |
XSC
X-Square Capital
Guaynabo,
Puerto Rico
|
+$486K |
| 3 |
WG
Winton Group
London,
United Kingdom
|
+$428K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$201K |
| 5 |
VF
Virtu Financial
New York
|
+$103K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.14M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$896K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$646K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$421K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$321K |
AVEO Hedge Fund Activity: Q3 2019 in Review
59 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q3 2019, worth a combined $36.2M — up 13% from $31.9M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of AVEO and 8 opened new positions — a net loss of 13 holders — while 15 trimmed existing stakes and 15 added.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $1.47M. The largest seller was Millennium Management, cutting an estimated $2.14M.
- 59 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q3 2019, down from 73 in Q2 2019.
- Funds reported $36.2M of AVEO Pharmaceuticals, Inc. stock for Q3 2019, up 13% quarter-over-quarter.
- 8 funds opened new AVEO Pharmaceuticals, Inc. positions in Q3 2019 and 21 closed out, a net change of -13 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q3 2019 was 683 Capital Management, an estimated $1.47M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q3 2019 was Millennium Management, an estimated $2.14M sold.
Based on aggregated 13F filings for Q3 2019.